Inhibikase Therapeutics (IKT) EPS (Basic) Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) EPS (Basic) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 37.73% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 137.22% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | 53.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.64% |
| Dec 31, 2025 | 40.40% |
| Sep 30, 2025 | 49.26% |
| Jun 30, 2025 | 52.17% |
| Mar 31, 2025 | 47.15% |
| Dec 31, 2024 | 30.93% |
| Sep 30, 2024 | 14.23% |
| Jun 30, 2024 | 18.65% |
| Mar 31, 2024 | 21.64% |
| Dec 31, 2023 | 2.19% |
| Sep 30, 2023 | -22.34% |
| Jun 30, 2023 | -56.89% |
| Mar 31, 2023 | -37.30% |